MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.
Cure Today2d
Cancer Therapies Approved by the FDA in December 2024
The FDA approved several drugs in December for the treatment of diseases including pancreatic adenocarcinoma, lung cancer, ...
Pharmaceutical Technology5d
Calquence by AstraZeneca for Graft Versus Host Disease (GVHD): Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD).
Pharmaceutical Technology5d
TRX-103 by Tr1X for Graft Versus Host Disease (GVHD): Likelihood of Approval
TRX-103 is under development for the treatment of graft versus host disease (GvHD), Crohn’s disease and unspecified indication. The therapeutic candidate comprises of allogenic Treg-cells which are ...
Businessworld6d
CopyBet review
CopyBet review JAK1 inhibitor GVHD phase III clinical trial failed Gelesis Secures Over $84 Million in New Funding to Support Commercialization of PLENIT ...
Businessworld6d
fantasy cricket expert
fantasy cricket expert Strategies for the development of new drugs for graft-versus-host disease (GVHD) $100 million! Hausen Pharmaceuticals licenses EQRx to acquire rights to Ametinib outside China ...